Nα-1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-tyrosinol
Need Assistance?
  • US & Canada:
    +
  • UK: +

Nα-1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-tyrosinol

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
Amino Alcohol
Catalog number
BAT-002596
CAS number
220237-31-0
Molecular Formula
C19H25NO4
Molecular Weight
331.41
Nα-1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl-L-tyrosinol
IUPAC Name
(S)-2-(1-((1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl)amino)ethylidene)-5,5-dimethylcyclohexane-1,3-dione
Synonyms
1,3-Cyclohexanedione, 2-[1-[[(1S)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]ethyl]amino]ethylidene]-5,5-dimethyl-; 2-[1-[[(1S)-2-Hydroxy-1-[(4-hydroxyphenyl)methyl]ethyl]amino]ethylidene]-5,5-dimethyl-1,3-cyclohexanedione; Dde-L-Tyr-ol; 2-(1-{[(2S)-1-Hydroxy-3-(4-hydroxyphenyl)-2-propanyl]amino}ethylidene)-5,5-dimethyl-1,3-cyclohexanedione
Appearance
White Powder
Purity
≥95%
Density
1.189±0.06 g/cm3
Melting Point
115-122°C
Boiling Point
551.8±50.0°C at 760 mmHg
Storage
Store at 2-8°C
InChI
InChI=1S/C19H25NO4/c1-12(18-16(23)9-19(2,3)10-17(18)24)20-14(11-21)8-13-4-6-15(22)7-5-13/h4-7,14,20-22H,8-11H2,1-3H3/t14-/m0/s1
InChI Key
RHXVDCUWFNYICS-AWEZNQCLSA-N
Canonical SMILES
O=C1C(C(=O)CC(C)(C)C1)=C(NC(CO)CC2=CC=C(O)C=C2)C
1. Design, synthesis, in vitro, in vivo and in silico pharmacological characterization of antidiabetic N-Boc-l-tyrosine-based compounds
Miguel Ángel Herrera-Rueda, et al. Biomed Pharmacother. 2018 Dec;108:670-678. doi: 10.1016/j.biopha.2018.09.074. Epub 2018 Sep 21.
In this study, we synthesized five N-Boc-L-tyrosine-based analogues to glitazars. The in vitro effects of compounds 1-5 on protein tyrosine phosphatase 1B (PTP-1B), peroxisome proliferator-activated receptor alpha and gamma (PPARα/γ), glucose transporter type-4 (GLUT-4) and fatty acid transport protein-1 (FATP-1) activation are reported in this paper. Compounds 1 and 3 were the most active in the in vitro PTP-1B inhibition assay, showing IC50s of approximately 44 μM. Treatment of adipocytes with compound 1 increased the mRNA expression of PPARγ and GLUT-4 by 8- and 3-fold, respectively. Moreover, both compounds (1 and 3) also increased the relative mRNA expression of PPARα (by 8-fold) and FATP-1 (by 15-fold). Molecular docking studies were performed in order to elucidate the polypharmacological binding mode of the most active compounds on these targets. Finally, a murine model of hyperglycemia was used to evaluate the in vivo effectiveness of compounds 1 and 3. We found that both compounds are orally active using an exploratory dose of 100 mg/kg, decreasing the blood glucose concentration in an oral glucose tolerance test and a non-insulin-dependent diabetes mellitus murine model. In conclusion, we demonstrated that both molecules showed strong in vitro and in vivo effects and can be considered polypharmacological antidiabetic candidates.
2. Mechanistic studies of peroxynitrite-mediated tyrosine nitration in membranes using the hydrophobic probe N-t-BOC-L-tyrosine tert-butyl ester
Silvina Bartesaghi, Valeria Valez, Madia Trujillo, Gonzalo Peluffo, Natalia Romero, Hao Zhang, Balaraman Kalyanaraman, Rafael Radi Biochemistry. 2006 Jun 6;45(22):6813-25. doi: 10.1021/bi060363x.
Most of the mechanistic studies of tyrosine nitration have been performed in aqueous solution. However, many protein tyrosine residues shown to be nitrated in vitro and in vivo are associated to nonpolar compartments. In this work, we have used the stable hydrophobic tyrosine analogue N-t-BOC-L-tyrosine tert-butyl ester (BTBE) incorporated into phosphatidylcholine (PC) liposomes to study physicochemical and biochemical factors that control peroxynitrite-dependent tyrosine nitration in phospholipid bilayers. Peroxynitrite leads to maximum 3-nitro-BTBE yields (3%) at pH 7.4. In addition, small amounts of 3,3'-di-BTBE were formed at pH 7.4 (0.02%) which increased over alkaline pH; at pH 6, a hydroxylated derivative of BTBE was identified by HPLC-MS analysis. BTBE nitration yields were similar in dilauroyl- and dimyristoyl-PC and were also significant in the polyunsaturated fatty acid-containing egg PC. *OH and *NO2 scavengers inhibited BTBE nitration. In contrast to tyrosine in the aqueous phase, the presence of CO2 decreased BTBE nitration, indicating that CO3*- cannot permeate to the compartment where BTBE is located. On the other hand, micromolar concentrations of hemin and Mn-tccp strongly enhanced BTBE nitration. Electron spin resonance (ESR) detection of the BTBE phenoxyl radical and kinetic modeling of the pH profiles of BTBE nitration and dimerization were in full agreement with a free radical mechanism of oxidation initiated by ONOOH homolysis in the immediacy of or even inside the bilayer and with a diffusion coefficient of BTBE phenoxyl radical 100 times less than for the aqueous phase tyrosyl radical. BTBE was successfully applied as a hydrophobic probe to study nitration mechanisms and will serve to study factors controlling protein and lipid nitration in biomembranes and lipoproteins.
3. Rapid Synthesis of Boc-2',6'-dimethyl-l-tyrosine and Derivatives and Incorporation into Opioid Peptidomimetics
Aaron M Bender, Nicholas W Griggs, Chao Gao, Tyler J Trask, John R Traynor, Henry I Mosberg ACS Med Chem Lett. 2015 Oct 19;6(12):1199-203. doi: 10.1021/acsmedchemlett.5b00344. eCollection 2015 Dec 10.
The unnatural amino acid 2',6'-dimethyl-l-tyrosine has found widespread use in the development of synthetic opioid ligands. Opioids featuring this residue at the N-terminus often display superior potency at one or more of the opioid receptor types, but the availability of the compound is hampered by its cost and difficult synthesis. We report here a short, three-step synthesis of Boc-2',6'-dimethyl-l-tyrosine (3a) utilizing a microwave-assisted Negishi coupling for the key carbon-carbon bond forming step, and employ this chemistry for the expedient synthesis of other unnatural tyrosine derivatives. Three of these derivatives (3c, 3d, 3f) have not previously been examined as Tyr(1) replacements in opioid ligands. We describe the incorporation of these tyrosine derivatives in a series of opioid peptidomimetics employing our previously reported tetrahydroquinoline (THQ) scaffold, and the binding and relative efficacy of each of the analogues at the three opioid receptor subtypes: mu (MOR), delta (DOR), and kappa (KOR).
Online Inquiry
Verification code
Inquiry Basket